Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover (Q42988954)

12 November 2017

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

1 reference

Zeuzem S

1

1 reference

12 November 2017

Schmidt JM

2

1 reference

12 November 2017

Lee JH

3

1 reference

12 November 2017

von Wagner M

4

1 reference

12 November 2017

Teuber G

5

1 reference

12 November 2017

Roth WK

6

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

12 November 2017

1 reference

12 November 2017

28

1 reference

12 November 2017

245-252

1 reference

12 November 2017

1

1 reference

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

12 November 2017

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Quantification of hepatitis C virus RNA by competitive reverse transcription and polymerase chain reaction using a modified hepatitis C virus RNA transcript

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

A Simplex Method for Function Minimization

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Evaluation and propagation of confidence intervals in nonlinear, asymmetrical variance spaces. Analysis of ligand-binding data

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Parameter estimates from nonlinear models.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Hepatitis C virus infection is associated with the development of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepat

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Cytokine therapeutics: lessons from interferon alpha

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280132

7 January 2021

Identifiers

DOI

10.1002/HEP.510280132

1 reference

12 November 2017

1 reference